Summary
Since 2015, three CDK4/6 inhibitors (CDK4/6is) treatments, palbociclib, ribociclib, and abemaciclib, have been approved for treatment in combination with endocrine therapy, becoming the standard of care for first line treatment of HR+/HER2- metastatic breast cancer (mBC).
In the absence of RCTs to directly compare the effectiveness of the three CDK4/6is, this research used the Flatiron Health EHR-derived Panoramic database comprised of >740K patients with breast cancer to compare real-world progression free survival (rwPFS)of nearly 10,000 patients treated with palbociclib, ribociclib, and abemaciclib in combination with an aromatase inhibitor. This research found no significant rwPFS difference across the three CDK4/6is when treating patients with HR+/HER2- mBC.
Why this matters
This study is the largest real-world comparative analysis of rwPFS between the CDK4/6 inhibitors in combination with an AI conducted to date. Using novel real-world data solutions, this research provides evidence that improves our understanding of treatment options and outcomes for patients with mBC. Flatiron’s Panoramic datasets offer a scaled, comprehensive, disease-specific solution to answer questions not previously possible, unlocking critical information to improve care and outcomes for people with cancer.